INTRODUCTION {#s1}
============

Adenoid cystic carcinomas (ACCs) are relatively uncommon malignant epithelial neoplasms that can arise in a variety of gland-bearing organs most commonly in the head and neck region. They account for ∼1% of all head and neck malignancies and 10% of salivary gland tumors ([@MCS002626CHAC15]). ACCs demonstrate three main histologic patterns: solid, cribriform, and tubular ([@MCS002626CHAC14]). Low-grade (grade 1--2) ACCs exhibit a combination of cribriform and tubular patterns and are associated with slower rates of disease progression, including a 5-yr survival rate of ∼90%, with \<40% survival at 15 yr. Conversely, high-grade (grade 3) ACC, based on the presence of a significant proportion of tumor showing solid growth pattern, is associated with advanced-stage and more frequent development of late-onset distant metastases ([@MCS002626CHAC34]).

Because of the typically slow growth pattern of ACC, historically it has been difficult to assess the efficacy of systemic therapy in metastatic disease, and at present there are no reliable therapeutic options for long-term disease control of ACC ([@MCS002626CHAC11]; [@MCS002626CHAC15]). Molecular and genome-sequencing studies have begun to elucidate the genetic landscape of ACC in efforts to understand its pathophysiology and potentially alter its clinical course ([@MCS002626CHAC46]; [@MCS002626CHAC5]; [@MCS002626CHAC44]).

The use of whole-genome sequencing to inform clinical decision-making is an active area of research. Through the Personalized Oncogenomics project (POG) at the British Columbia Cancer Agency (Vancouver, Canada), we have established a pipeline that generates a comprehensive molecular analysis of individual cancer patients with advanced malignancies ([@MCS002626CHAC33]). The aims of these analyses are both to further elucidate and catalog cancer genomes in a metastatic setting and to provide patients with rational treatment options by using genomic data to identify available systemic therapies or active clinical trials. By performing whole-genome and transcriptome sequencing of five patients with ACC, we confirmed a role for the well-characterized *MYB-* and *MYBL1-NFIB* gene fusions in ACC pathogenesis and identified actionable targets that helped to inform therapy decisions in three of the five patients.

RESULTS {#s2}
=======

Clinical and Histological Data {#s2a}
------------------------------

Between 2012 and September 2017, five patients with ACC were enrolled in POG with an average age of 46.2 (SD 9.68) at time of diagnosis. Of the five cases, three patients presented with tumors originating from the head and neck. The other two cases presented with primary tumors at the trachea (POG 1 and POG 2), which are rare but described in the literature ([@MCS002626CHAC24]). Interestingly, none of our cases had tumors originating from the major or minor salivary glands, though POG 3 with primary ACC of the hard palate had evidence of invasion into the salivary gland. All patients had evidence of metastatic disease prior to POG analysis. Primary treatments included localized debulking surgery (in four of five cases, including laser bronchoscopy in POG 1) and radiation therapy (in all five cases, including brachytherapy in POG 1). Patient 4 received systemic therapy involving vinorelbine followed by gemcitabine and carboplatin prior to enrollment in the POG program. The average time from diagnosis to enrollment in POG was 8.6 yr ranging from 1 to 24 yr (SD 9.07), thereby highlighting the indolent but persistent nature of ACCs ([Table 1](#MCS002626CHATB1){ref-type="table"}).

###### 

Patient characteristics

  Patient   Sex   Age at Dx   Year of Dx   Location of primary          Metastases sites                      Treatment before POG biopsy                                  Year of POG consult   Biopsy site
  --------- ----- ----------- ------------ ---------------------------- ------------------------------------- ------------------------------------------------------------ --------------------- ----------------
  1         M     45          2009         Distal trachea               Lung                                  Multiple laser bronchoscopies, XRT (45 Gy), brachytherapy    2013                  Trachea
  2         F     44          1991         Trachea                      Lung                                  Partial tracheotomy, XRT (55 Gy), lung met wedge resection   2015                  Lung nodule
  3         M     34          2007         Right hard palate            Lung                                  Resection, XRT                                               2016                  Lung nodule
  4         M     61          2015         Left maxillary sinus/orbit   Lung, liver, T11 vertebra             Left orbital exenteration and reconstruction, XRT (60 Gy)    2016                  Liver
  5         M     47          2011         Floor of mouth               Tongue, mylohyoid, myoglossus, lung   XRT (70 Gy)                                                  2016                  Floor of mouth

Dx, diagnosis; POG, Personalized Oncogenomics program; XRT, radiotherapy.

Biopsies were obtained from either primary site recurrences or metastases for POG analysis. Notably, histopathologic evaluation of our samples correlated with their clinical course. For example, biopsy of POG 1 revealed a grade 2 ACC characterized by cribriform and tubular patterns, and no evidence of perineural or lymphovascular invasion, which correlates with slower progression over several years ([Fig. 1](#MCS002626CHAF1){ref-type="fig"}A). Conversely, biopsy of POG 4 revealed a grade 3 ACC characterized by cribriform and solid patterns as well as extensive perineural and lymphovascular invasion, which is reflected in its rapid progression and distant metastases to the bone ([Fig. 1](#MCS002626CHAF1){ref-type="fig"}B).

![Hematoxylin and eosin staining images of representative POG ACC cases at 100× original magnification: (*A*) POG 1, (*B*) POG 2.](MCS002626Cha_F1){#MCS002626CHAF1}

Mutational and Expression Landscape of ACC {#s2b}
------------------------------------------

Whole-genome and transcriptome sequencing was performed on the five samples, and we identified somatic mutations in 112 genes among the cases ([Supplemental Table 1](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a002626/-/DC1)). An average of 21.40 protein coding single-nucleotide variants (SNVs) were identified between samples (ranging from 12 to 39). The number of protein coding small insertions and deletions (indels) ranged from one to seven across the five samples, with an average of 3.40. Notably, POG 5 had a considerably higher number of SNVs than the other samples ([Fig. 2](#MCS002626CHAF2){ref-type="fig"}A). The only genes identified with greater than one mutation among these five samples were *BAP1*, manifesting as SNVs in POG 4 and POG 5, and *BCOR*, manifesting as a truncating SNV in POG 2 and frameshifting indels in POG 1 and POG 5 ([Fig. 2](#MCS002626CHAF2){ref-type="fig"}B). Notably, BCOR is mutated in \<15% of tumors of any type across TCGA, but contains putative loss-of-function mutations in 60% (3 of 5) of samples in our cohort ([Fig. 2](#MCS002626CHAF2){ref-type="fig"}C). *BAP1* is a tumor suppressor that encodes a deubiquitinating enzyme regulating key cellular pathways ([@MCS002626CHAC53]), whereas *BCOR* is a *BCL6* corepressor mutated in various sarcomas and hematological diseases ([@MCS002626CHAC51]).

![Mutational landscape of ACC. (*A*) Number of single-nucleotide variations (SNVs) and short insertion and deletions (indels) in five cases of ACC. (*B*) Oncoprint depicting small mutations and recurrent fusions in known cancer-related genes, POG1 to POG5 from *right* to *left*. (*C*) Frameshifting mutations observed in BCOR occur throughout the protein, at amino acids 133, 1303, and 1562.](MCS002626Cha_F2){#MCS002626CHAF2}

Despite the low frequency of mutations, sequencing of the entire genomes produces sufficient variants for analysis of mutational signatures ([@MCS002626CHAC2]) in ACC. All five cases showed evidence of C\>T base changes consistent with deamination associated with natural aging processes ([Table 2](#MCS002626CHATB2){ref-type="table"}; [Supplemental Fig. 1A](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a002626/-/DC1)). In addition, all but one case showed evidence of signature 5, which has an unknown etiology but is commonly observed across cancer types. Furthermore, four of five cases showed evidence for signature 16, also with no known association. Examining the relationship between signature probabilities, we observed a significant anticorrelation between signatures 5 and 16 in all four cases with elevated signature 16, suggesting bleed of signal between these two similar mutation signatures ([Supplemental Fig. 1B](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a002626/-/DC1); Spearman ρ \< −0.6). This provides evidence that the presence of signature 16 may be driven by signature 5 elevation rather than representing an additional source of mutations. Table 2.Variant tableSampleGeneChromosomeHGVS DNA referenceHGVS protein referenceVariant typePredicted effectdbSNP/COSMIC IDGenotypePOG 1*BCOR*Xc.398_399insACp.Ala134fsinsFrameshiftHomozygousPOG 1*MECOM*3c.1636C\>Tp.Gln546\*snvTruncatingHeterozygousPOG 2*BCOR*Xc.3961G\>Tp.Glu1321\*snvTruncatingHeterozygousPOG 2*NOTCH1*9c.2825G\>Ap.Cys942TyrsnvMissenseHeterozygousPOG 2*NOTCH1*9c.4045_4052del GCTCGTACp.Ala1349fsdelFrameshiftHeterozygousPOG 4*BAP1*3c.188C\>Gp.Ser63CyssnvMissenseCOSM96362HomozygousPOG 4*FGFR2*10c.1144T\>Cp.Cys382ArgsnvMissensers121913474; COSM915496HeterozygousPOG 5*ARID2*12c.2989C\>Tp.Gln997\*snvTruncatingHeterozygousPOG 5*BAP1*3c.374A\>Cp.Glu125AlasnvMissenseHeterozygousPOG 5*BCOR*Xc.4685_4700del GCACTTGGGACTTCTAp.Gly1562fsdelFrameshiftHeterozygousPOG 5*JAK3*19c.1765G\>Ap.Gly589SersnvMissenseHeterozygousPOG 5*KRAS*12c.34G\>Cp.Gly12ArgsnvMissensers121913530HeterozygousPOG 5*SMARCA2*9c.3638G\>Cp.Arg1213ProsnvMissenseHeterozygousPOG 5*SMARCB1*22c.110G\>Cp.Arg37ProsnvMissenseHeterozygousPOG 5*STAT3*17c.1467T\>Ap.Asn489LyssnvMissenseHeterozygous[^1]

In addition to a low mutation load, we observed only a low level of copy-number alterations in these tumors, with genomes of three samples predominantly copy neutral with small numbers of deletions, and POG 4 and POG 5 showing in addition some limited regions of amplification ([Supplemental Fig. 2](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a002626/-/DC1)). No genes were subject to homozygous deletion or amplification in more than one sample. POG 4 contained a homozygous deletion of CDKN2A/B (p16) and corresponding decrease in expression. POG 5 showed amplification on 8q24 containing MYC and associated increased MYC expression; MYC also showed increased expression in POG 2 and POG 4 but without associated amplification.

We additionally compared gene expression in our five samples to 40 different primary tumor types, including 37 primary (sub)types from the Cancer Genome Atlas (TCGA) ([@MCS002626CHAC52]). The frequency of mutations in our cases was notably low, with percentiles of 36%, 29%, 21%, and 22% for samples 1--4, respectively, relative to TCGA. Sample 5 had a higher mutation rate, presenting in the 65th percentile relative to TCGA tumors. Of note, this comparator set of cancers does not contain any samples of ACC. However, four of the five samples showed similarity to primary breast cancer (BRCA) despite originating from different tissues ([Supplemental Fig. 3](http://www.molecularcasestudies.org/lookup/suppl/doi:10.1101/mcs.a002626/-/DC1)). POG 3 showed a similar pattern but with increased similarity to thoracic tumors, likely corresponding to the lung nodule biopsy site of this tumor. To examine further the association with breast cancer, we used the AIMS classifier ([@MCS002626CHAC42]) to determine if any of the ACCs had further similarities to specific breast cancer subtypes. We found that POG 1 and POG 4 were classified as basal, corresponding to mostly triple negative breast tumors.

Together, this analysis demonstrates that there are no striking mutational processes active in ACC, consistent with the low mutational burden in these tumors. Furthermore, the lack of characterization of ACC in TCGA demonstrates a rationale for in-depth genomic analysis of ACC.

Structural Variations {#s2c}
---------------------

To evaluate structural variations in our five samples, we assessed gene fusion products at the genomic and transcriptomic level ([Fig. 3](#MCS002626CHAF3){ref-type="fig"}A,B). Previous work has implicated the t(6;9) translocation between the *MYB* oncogene and the transcription factor *NFIB* as a prominent driver of ACC pathophysiology found in the majority of tumors ([@MCS002626CHAC38]; [@MCS002626CHAC23]). Our analysis elucidated that four of five samples exhibited the *MYB-NFIB* translocation at the genome and transcriptome level, with POG 3, POG 4, and POG 5 creating identical fusion products with chromosomal breaks after exon 8 of *MYB* ([Fig. 4](#MCS002626CHAF4){ref-type="fig"}A). POG 2 also harbored the *MYB-NFIB* translocation, but with the chromosomal break after exon 12 ([Fig. 4](#MCS002626CHAF4){ref-type="fig"}B). Of note, POG 1 exhibited a more recently characterized t(8;9) translocation between *MYBL1*, a distinct *MYB*-family transcription factor, and *NFIB*, demonstrated in both the genome and transcriptome sequencing ([Fig. 4](#MCS002626CHAF4){ref-type="fig"}C; [@MCS002626CHAC7]; [@MCS002626CHAC40]). Interestingly, the *MYB-NFIB* fusion product was the only translocation present in the transcriptomes of POG 2 and 3. Furthermore, *MYB, MYBL1,* and *NFIB* were not involved in any structural variations with other genes in our cases. Our data therefore confirms the importance of the *MYB-NFIB* translocation in the pathogenesis of ACC, as a variation of the fusion that was present in the transcriptome of all of our cases.

![Structural variants in the (*A*) genome and (*B*) transcriptome of five cases of ACC.](MCS002626Cha_F3){#MCS002626CHAF3}

![*MYB-NFIB* fusions. (*A*) Schematic representation of the well-characterized *MYB-NFIB* fusion (t\[6;9\]) identified in both the genome and transcriptome of POG 3. POG 4 and 5 created completely identical fusion products with breaks in the same introns. (*B*) Schematic representation of *MYB-NFIB* fusion in POG 2, with breakpoint at exon 12. (*C*) Schematic representation of the lesser characterized *MYBL1-NFIB* fusion (t\[8;9\]) identified in POG 1 involving a related, but distinct *MYB*-family transcription factor. Blue, MYB or MYBL1; green, NFIB; numbered boxes, exons; black boxes, protein coding region; F1, predicted fusion product.](MCS002626Cha_F4){#MCS002626CHAF4}

Identification of Potential Therapeutic Targets and Clinical Outcomes {#s2d}
---------------------------------------------------------------------

Targeted therapies for advanced ACC are currently under investigation in early phase clinical trials. Because of the rarity of ACC and the relatively low mutational burden, most of drugs in trials have been selected based on observations from preclinical studies. [Table 3](#MCS002626CHATB3){ref-type="table"} highlights some of the targeted agents investigated in phase II trials for advanced ACC. Of note, there were no trials in which complete response was established.

###### 

Phase II trials of targeted agents in adenoid cystic carcinoma

  Agent        Molecular target                    Authors                 *N*      Partial response  Stable disease
  ------------ ----------------------------------- -------------------- ---------- ------------------ ----------------
  Imatinib     c-KIT CD117                         [@MCS002626CHAC27]       10             0          2 (20%)
  Lapatanib    HER-2, EGFR                         [@MCS002626CHAC1]        19             0          15 (79%)
  Cetuximab    EGFR                                [@MCS002626CHAC35]       23             0          20 (87%)
  Bortezomib   Proteosome inhibitor                [@MCS002626CHAC4]        25             0          16 (64%)
  Sunitinib    VEGFR, c-KIT, PDGFR                 [@MCS002626CHAC13]       13             0          11 (62%)
  Gefitinib    EGFR TKI                            [@MCS002626CHAC28]       19             0          13 (68%)
  Axitinib     VEGFR, KIT, PDGFR                   [@MCS002626CHAC26]       33           3 (9%)       25 (76%)
  Dasatinib    c-KIT, PDGFR                        [@MCS002626CHAC55]    40 (ACC)       1 (2.5%)      20 (50%)
  Nintedanib   VEGFR, FGFR, PDGFR                  [@MCS002626CHAC31]       20             0          15 (75%)
  Vorinostat   Histone deacetylase inhibitor       [@MCS002626CHAC22]       30          2 (6.7%)      27 (90%)
  Dovitinib    VEGFR, PDGFR, FGFR, c-KIT, CSF-1R   [@MCS002626CHAC16]       34           2 (6%)       22 (65%)

HER-2, human epidermal receptor-2; EGFR, epidermal growth factor receptor; VEGFR, vascular endothelial growth factor receptor; PDGFR, platelet-derived growth factor receptor; TKI, tyrosine kinase inhibitor; FGFR, fibroblast growth factor receptor; CSF-1R, colony stimulating factor-1 receptor.

POG analysis in all five of our ACC cases yielded informative and actionable results, meaning that potential targets or risk factors that could affect treatment plans were identified for all five patients ([Table 4](#MCS002626CHATB4){ref-type="table"}). We elucidated potential therapeutic targets by identifying mutated genes or genes that were overexpressed relative to TCGA and through subsequent literature review for drug-targeted combinations. Results were deemed "actionable" by an interdisciplinary tumor board based on options that are clinically available and relevant to the patient as determined by tumor characteristics, patient characteristics (including performance status), and drug availability. A summary was created that allowed clinicians involved to make a treatment decisions ([@MCS002626CHAC33]). Three of the five patients have thus far received POG-informed systemic therapy.

###### 

POG analyses in all five adenoid cystic carcinoma cases yielded informative and actionable results

  Patient   Potential therapeutic targets                                                                                          Actionable targets                                               Action taken
  --------- ---------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------- ------------------------------------------------------
  1         *KIT, FGFR1/2/L1, CDK1/B1/3/6, GADD45B, CCNB, PLK1, TGFA, EGFR, ERBB2, TGFA, AREG, TUBA1A/A1B/A1C, BIRC5, HMGA1*       *FGFR1/2/L1* overexpression                                      Dovitinib
  2         *CDK4/6, CCND1, MYC, ROS1, NTRK3, EIGF1R, GFR, KIT, FGFR1/2, PDGFRA, MET, SMO, GLI3, JAG2, NOTCH1, BCL2, FZD7, BCL2*   *NOTCH1* overexpression                                          BMS-986115 (P1T986115)
  3         *MYB, NFIB, EGFR, MET, FGFR1/2, ROS1, CDK6, MAP2K2, MMP7, FZD7*                                                        *MET* overexpression                                             MGCD265 (glesatinib)
  4         *ARFGEF3, CDKN2A/N2B, IGF1R, MYC, PRAME, SKP2, SCL29A1, FGFR1/2, KIT, ALK, RAS, RAF, NOTCH1, CTNNB1, WNT/FZD*          *FGFR2* gain of function                                         None (poor ECOG status)
  5         *FOLR1, IGF2, KRAS, MDK, MYC, PRAME, PVRL4, SKP2, PDGFA/B/C, FGFR1/2, KIT, IGF2, NOTCH1, HES1/4, FZD6/7, MMP7*         Aberrations in epigenetic regulators; *FGFR1/2* overexpression   Pending; potential for HDAC or FGFR antibody therapy

Potential targets or risk factors that could affect treatment plans were identified for all five patients. Three of five patients have thus far received POG-informed systemic treatment.

Based on overexpression of *FGFR*-related genes as determined by POG analysis, and preclinical data suggesting partial response to FGFR inhibition in xenograft models of ACC ([@MCS002626CHAC19]), Patient 1 was enrolled in a phase II clinical trial with dovitinib (TK1258), a multitargeted tyrosine kinase inhibitor with action against FGFRs 1--3, VEGFR, PDGFR, and c-KIT among other receptor kinases ([@MCS002626CHAC12]). This patient withdrew from the trial after 4 months because of intolerable side effects, despite having stable disease (as measured by \<20% change in tumor size on CT scan). The patient subsequently underwent further palliative radiotherapy before transitioning to palliative care.

POG analysis of Patient 2 did not suggest any commercially available targeted therapies. However, multiple targets with potentially experimental therapies were elucidated. Analysis revealed a NOTCH1 truncating deletion at amino acid 1349, a single base mutation C942Y of unknown effect, *NOTCH1* pathway up-regulation, and up-regulation of downstream targets including *BCL2, MYC*, and *CCND1*. NOTCH1 signaling has been shown to occur frequently in ACC and may contribute to cell growth and metastasis in these tumors ([@MCS002626CHAC49]; [@MCS002626CHAC41]). Accordingly, Patient 2 was enrolled in a phase I clinical trial with BMS-986115 (Bristol Myers Squibb), a γ secretase and pan-NOTCH inhibitor. Dose reduction was required early, and the patient withdrew from the trial because of toxicity after 2 months and before a response could be determined.

Patient 3 exhibited aberrations in *MET* expression and was subsequently enrolled in a phase I clinical trial with MGCD265, a multitarget and ATP-competitive inhibitor of c-MET and VEGFR1/2/3 that has recently been studied in lung cancer models ([@MCS002626CHAC17]). The patient remained clinically stable for several months while on the study, but was removed after 8 months because of increasing tumor size.

Potential therapeutic targets in phase 1 trials were identified for Patient 4, but the patient was not offered POG-mediated intervention because of declining functional status. POG analysis of Patient 5 revealed aberrations in multiple epigenetic modifiers including ARID2, SMARCA2, and SMARCB1 that would suggest a role for intervention with histone deacetylase inhibitors such as vorinostat, which has recently been studied in ACC in a phase II trial ([@MCS002626CHAC22]). This patient continues to have stable disease and therefore has not yet undergone any POG-informed therapeutic intervention.

DISCUSSION {#s3}
==========

Several recent studies have investigated the molecular landscape of ACC with a focus on primary tumors, yet there remains a gap in knowledge regarding characterization of recurrent and metastatic ACC and how to treat these tumors. Through the Personalized Oncogenomics project we have elucidated recurrent mutations among five cases of metastatic ACC and identified therapeutic targets that were implemented into clinical decisions guiding treatment for three of the five cases. It is unfortunate that the drugs in available trials were highly toxic and thus the true effect of inhibiting these active pathways remains unclear.

Approximately 55%--60% of ACCs originate in the head and neck, with the majority arising from the major salivary glands ([@MCS002626CHAC30]; [@MCS002626CHAC46]). Accordingly, several molecular sequencing studies of ACC have focused on these subtypes ([@MCS002626CHAC48]; [@MCS002626CHAC5]; [@MCS002626CHAC41]). Interestingly, none of our patients had cancers derived from the major salivary gland. Two cases originated from the mid respiratory tract, which account for ∼20% of ACCs ([@MCS002626CHAC24]). Though our sample size is insufficient to generate broad conclusions, our genomic and transcriptomic analysis help to further characterize less represented subtypes of this relatively rare cancer.

The five cases presented exhibit a low mutational burden in keeping with previous studies ([@MCS002626CHAC25]; [@MCS002626CHAC41]). Indeed, analysis of mutational signatures in our samples did not elucidate any known mutational process driving tumor growth beyond those commonly observed in many cancer types. Interestingly, however, signature 5 is abundant despite the fact that it has not been found to correlate with age in head and neck cancers ([@MCS002626CHAC3]). This, alongside the bleed between signatures 5 and 16, may suggest a yet uncharacterized mutational process or a different role of signature 5 in ACC. Despite infrequency of mutations, whole-genome and transcriptome analyses have revealed a number of alterations that may contribute to ACC tumorigenesis including mutations in *NOTCH1* ([@MCS002626CHAC44]) and *SMARCA2* ([@MCS002626CHAC48]; [@MCS002626CHAC11]). Our study is the first to recognize recurrent mutations in *BAP1* and *BCOR* in ACC and suggests that these alterations may play a role in the pathogenesis of metastatic ACC. *BAP1* gene mutations have been implicated in various malignancies including uveal and cutaneous melanoma, renal cell carcinoma, and mesothelioma ([@MCS002626CHAC9]), whereas *BCOR*-inactivating mutations have been identified in various hematologic malignancies ([@MCS002626CHAC51]). Thus far neither have been associated with ACC. The low frequency of mutations in ACC limits the identification of potentially useful therapeutic targets, which underscores the importance of identifying novel recurrent mutations that contribute to tumor profiling.

Further highlighting the low mutational burden of ACC, four of our five cases had mutational rates below the 40th percentile relative to TCGA, which is consistent with the well-described indolent course of ACC tumor growth. Of note, mutational burden does not seem to correlate with tumor aggressiveness in our cohort. Although POG 5 had the highest mutation rate, it was not characterized by rapid clinical progression, and thus far the patient has been stably managed with localized treatment. Conversely, POG 4 exhibited the second lowest mutational burden in our samples and was characterized by high-grade solid and cribriform histology and rapid progression with distant metastases to the bone, which is known to be associated with poor outcome ([@MCS002626CHAC50]). Interestingly, comparison with tumors in TCGA also revealed similarities in the expression profiles of our cases and breast cancer tissue. This may reflect the histologic and genetic similarity among ACCs irrespective of anatomical origin site that has been previously reported ([@MCS002626CHAC36]; [@MCS002626CHAC37]). ACC of the breast, which accounts for \<1% of breast cancers and displays a triple negative and basal-like phenotype ([@MCS002626CHAC54]), demonstrates similarity to salivary gland ACC based on the presence of the *MYB-NFIB* fusion gene ([@MCS002626CHAC43]; [@MCS002626CHAC20]). The recurrent *MYB-NFIB* fusion demonstrated in our study may therefore rationalize the similarity with TCGA breast cancer samples.

Indeed, our analysis revealed *MYB-NFIB* fusions in four of five cases, with the fifth case exhibiting the closely related *MYBL-NFIB* fusion. Prior studies have described *MYB-NFIB* fusions to be a hallmark genetic event in ACC based on its incidence in 50%--60% of tumors ([@MCS002626CHAC38]; [@MCS002626CHAC25]), and its presence in the majority of our cases further highlights its role as a driver mutation. Tumors with *MYB* and *MYBL1* translocation have been shown to have similar gene expression profiles, and the translocation of *MYB/MYBL* and *NFIB* activates several target genes associated with apoptosis, cell cycle control, cell adhesion, growth, differentiation, and angiogenesis ([@MCS002626CHAC18]). Among our cases, notable genes downstream from the *MYB-NFIB* fusion that were altered or overexpressed included *KIT, MYC, PRAME, FGFR2, BCL2*, and *CDK6*. The *MYB-NFIB* fusion has been associated with poorer outcome of salivary ACC ([@MCS002626CHAC39]), and its prevalence among our cohort may suggest that it has a more significant role in the pathogenesis of rare and metastatic ACC, and can provide insight into targeted therapy for these cancers.

Although previous studies have elucidated potential therapeutic targets based on whole-genome and transcriptome sequencing of ACC ([@MCS002626CHAC25]; [@MCS002626CHAC41]), to our knowledge ours is the first study to implement such findings into direct clinical action. Among the five cases, three were treated with POG-informed therapy; specifically a multitargeted tyrosine kinase inhibitor (dovitinib), a pan-NOTCH inhibitor, and a multitarget and ATP-competitive inhibitor of c-MET and VEGFR1/2/3, all of which were in phase I or II clinical trials at the time. In a recently published phase II clinical trial, [@MCS002626CHAC16] demonstrated that dovitinib had antitumor activity in patients with recently progressed ACC, but came at the expense of moderate toxicity with one in five patients having to withdraw because of intolerable side effects. Aligning with these observations, Patient 1, who underwent treatment with dovitinib based on overexpression of *FGFR*- related genes, had to withdraw from the trial. Similarly, Patient 2 chose to cease treatment with a pan-NOTCH inhibitor after requiring several dose reductions. Unfortunately both the pan-NOTCH inhibitor and dovitinib have subsequently halted development primarily because of toxicity and before efficacy could be established. Therefore, other therapeutics will need to be investigated to fulfill the need for targeting these pathways. However, despite these outcomes, our POG analysis identified possible targets within aberrant cancer-related pathways and therapeutic trials that hold potential to be effective for patients based on their genomic landscape.

In summary, our data provide insights into the genetic landscape of rare and metastatic ACC and establish that whole-genome and transcriptome sequencing can effectively yield potential therapeutic options for the treatment of these rare cancers.

METHODS {#s4}
=======

Oversight, Ethics, and Patient Sample Collection {#s4a}
------------------------------------------------

The study was approved by the University of British Columbia Research Ethics Committee (REB\# H14-00681), and written informed consent was obtained from each patient before biopsy and genomic profiling. Consent was also obtained for potential publication of findings. Patient data were de-identified within the research team and identification codes were assigned for communicating clinically relevant information to physicians. Raw sequence data and downstream analytics were maintained within a secure computing environment.

Whole-Genome and Transcriptome Sequencing {#s4b}
-----------------------------------------

Fresh frozen biopsies were obtained and intermittent hematoxylin and eosin (H&E)-stained slides were reviewed for tumor content and cellularity. DNA and RNA extractions were performed on OCT-embedded tumor samples using either the AllPrep DNA/RNA Mini Kit (QIAGEN) or the ALine EvoPure kit (Aline Biosciences) to create genomic and transcriptomic libraries. Additionally, DNA was isolated from peripheral blood for sequencing library construction.

PCR-free libraries were constructed for tumor and normal DNA samples, and strand-specific libraries were constructed for tumor RNA samples, as described previously ([@MCS002626CHAC29]). Whole-genome sequencing (WGS) was performed to 80× redundant coverage of the tumor and 40× redundant coverage of the normal, and transcriptome sequencing (RNA-seq) was performed to a depth of 200 million reads, using Illumina HiSeq instruments with 125- or 150-bp paired-end reads (Illumina; <http://www.illumina.com>) (see [Table 5](#MCS002626CHATB5){ref-type="table"}).

###### 

Sequencing coverage of aligned reads

  Sample   Tumor DNA coverage (WGS)   Normal DNA coverage (WGS)   Tumor RNA coverage (RNA-seq)
  -------- -------------------------- --------------------------- ------------------------------
  POG 1    73×                        44×                         408 M reads
  POG 2    88×                        45×                         183 M reads
  POG 3    98×                        50×                         70 M reads
  POG 4    88×                        41×                         161 M reads
  POG 5    100×                       50×                         173 M reads

Somatic Alteration Analysis {#s4c}
---------------------------

An established analytical pipeline was used for identifying somatic nucleotide and copy-number aberrations throughout the genome from tumor DNA in comparison to normal DNA from the same patient, as previously described ([@MCS002626CHAC29]). De novo assembly of genomic and transcriptomic data was carried out using ABySS ([@MCS002626CHAC45]) and Trans-ABySS ([@MCS002626CHAC6]; [@MCS002626CHAC47]) to detect structural rearrangements and fusions. Copy number and LOH were visualized with Circos ([@MCS002626CHAC32]). Gene fusions were evaluated and visualized using MAVIS (<http://mavis.bcgsc.ca/>). Visualization of gene alterations by sample was through OncoPrinter and MutationMapper, and recurrence of mutations across TCGA was determined through CBioPortal (<http://www.cbioportal.org/>) ([@MCS002626CHAC10]; [@MCS002626CHAC21]). Mutation signatures were computed based on genome-wide single-nucleotide variant calls and trinucleotide contexts as previously described ([@MCS002626CHAC2]) and compared to COSMIC reference signatures (<http://cancer.sanger.ac.uk/cosmic/signatures>). Signature scores represent the fraction of mutations contributed by a particular signature. To examine the relationship between signatures, in particular signatures 5 and 16, we used a hierarchical Bayesian categorical mixture model to explore the posterior distribution of signature exposures (E Zhao, S Jones, in prep.).

Expression Analysis and Comparison with TCGA Data Sets {#s4d}
------------------------------------------------------

Expression levels of each gene were derived from aligned RNA-Seq reads as described in [@MCS002626CHAC8] ([@MCS002626CHAC29]). Gene expression in the ACC samples was compared to available tumor samples from multiple cancer types in the Cancer Genome Atlas (TCGA; <https://tcga-data.nci.nih.gov/tcga/>) as well as normal samples from Illumina Human Body Map 2.0 to identify genes over- or underexpressed, as described in [@MCS002626CHAC29]. Similarity to TCGA cancer types was determined by a machine learning based pan-cancer classifier trained on whole-transcriptome profiles of TCGA primary cancers (J Grewal, S Jones, in prep.)
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Data Deposition and Access {#s5a}
--------------------------

The whole-genome sequencing and RNA-seq data for this case are available as .bam files from the European Genome-phenome Archive (EGA; [www.ebi.ac.uk/ega/home](www.ebi.ac.uk/ega/home)) as part of the study EGAS00001001159, under accession numbers EGAD00001002032 (Patient 1), EGAD00001002627 (Patient 2), EGAD00001003065 (Patient 3), EGAD00001003640 (Patient 4), and EGAD00001003679 (Patient 5). Somatic variants were deposited in ClinVar (<https://www.ncbi.nlm.nih.gov/clinvar/>) under accession numbers SCV000693656 (*BCOR*, patient 1), SCV000693657 (*MECOM*, patient 1), SCV000693671 (*MYBL1-NFIB* fusion, patient 1), SCV000693658 (*BCOR*, patient 2), SCV000693659 (*NOTCH1*, patient 2), SCV000693660 (*NOTCH1*, patient 2), SCV000693672 (*MYB-NFIB* fusion, patient 2), SCV000693673 (*MYB-NFIB* fusion, patient 3), SCV000693661 (*BAP1*, patient 4), SCV000693662 (*FGFR2*, patient 4), SCV000693674 (*MYB-NFIB* fusion, patient 4), SCV000693663 (*ARID2*, patient 5), SCV000693664 (*BAP1*, patient 5), SCV000693665 (*BCOR*, patient 5), SCV000693666 (*JAK3*, patient 5), SCV000693667 (*KRAS*, patient 5), SCV000693668 (*SMARCA2*, patient 5), SCV000693669 (*SMARCB1*, patient 5), SCV000693670 (*STAT3*, patient 5), and SCV000693675 (*MYB-NFIB* fusion, patient 5).
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[^1]: HGVS, Human Genome Variation Society; dbSNP, Single Nucleotide Polymorphism database; COSMIC, Catalogue of Somatic Mutations in Cancer; ins, insertion; snv, single-nucleotide variant; del, deletion.
